Zymeworks Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kenneth H. Galbraith
- Full Time Employees
- 264
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 108 Patriot Drive Middletown DE United States of America 19709
- IPO Date
- Apr 28, 2017
- CIK
- 0001937653
- Website
- zymeworks.com
- Similar Companies
- Business
- Zymeworks Inc. (Nasdaq: ZYME) is a clinical-stage biotechnology company that develops and commercializes multifunctional biotherapeutics targeting difficult-to-treat cancers and other diseases. The company engineers Azymetric and Zymabod platforms to create bispecific antibodies and multispecific antibody-based molecules; its product candidates include zanidatamab, a HER2-targeting bispecific antibody in Phase 3 trials for biliary tract cancer partnered with Jazz Pharmaceuticals, as well as ZW171, ZW220, and other preclinical and early-stage assets targeting solid tumors and hematologic malignancies. Zymeworks offers contract research and development services through its subsidiaries, focusing on protein engineering and therapeutic design for oncology and autoimmune indications. Founded in 2010 and headquartered in Vancouver, Canada, the company operates primarily in North America with clinical trials and partnerships extending to Europe and Asia. In the last two years, Zymeworks completed a significant strategic transaction with Iconic Therapeutics in 2024, acquiring full global rights to zanidatamab and related HER2-targeted programs following Jazz Pharmaceuticals' return of rights in late 2023, enabling accelerated independent development. The company raised approximately CAD 92 million through a public offering in 2024 to fund zanidatamab's Phase 3 HERIZON-BTC-01 trial and other pipeline advancement. Zymeworks also advanced ZW171 into a Phase 1 trial in 2025 for advanced or metastatic solid tumors, marking a key expansion of its ROR1-targeted portfolio, while streamlining operations to focus on high-potential clinical assets amid a challenging biotech funding environment.
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma
Theravance Stock Down 3% After Zymeworks Announces Buyout
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks strikes $929 million deal for Theravance Biopharma
Zymeworks to Acquire Theravance Biopharma, Inc.
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC Optionality
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Q1 Earnings Call Highlights
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
Zymeworks (NASDAQ:ZYME) and ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Contrast
Zymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar Ziihera
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of “Moderate Buy” from Analysts